Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Systematic Review: Targeting HER2 in Bladder Cancer

Systematic Review: Targeting HER2 in Bladder Cancer Background:HER2 (ErbB2) is a receptor of the Human Epidermal Growth Factor Receptor (HER) family whose role in oncogenesis of numerous malignancies is well described. Drugs targeting HER2 are currently approved in breast and gastroesophageal cancers while pan-HER targeting agents are being evaluated in multiple malignancies. HER2 genomic alterations are commonly described in urothelial cancer and multiple trials have assessed the efficacy of anti-HER2 agents in both muscle-invasive and metastatic urothelial carcinoma.Objective:To review prospective clinical trials of therapeutic agents with HER2– targeting activity in patients with bladder cancer.Methods:A systematic search of PubMed, ASCO abstracts and Clinicaltrials.gov was performed to identify studies of HER2– targeting agents in bladder cancer. Reported results from prospective trials were reviewed and summarized.Results:Eleven prospective clinical trials with reported results were identified that investigated activity of trastuzumab, lapatinib, neratinib, afatinib, or autologous cellular immunotherapy (DN24–02) in various bladder cancer treatment settings. Another 11 prospective trials that include bladder cancer patients and are investigating agents with anti-HER2 activity are currently ongoing or have completed enrollment but do not have published results. The reported clinical trials had variable HER2– positivity inclusion criteria and most did not meet their pre-specified benchmarks of clinical efficacy. A recent afatinib trial in an unselected patient population had promising findings in patients with HER2 and HER3 alterations.Conclusion:Trials of HER2– targeting agents generally in unselected bladder cancer patients have not shown definitive clinical efficacy. Better patient selection, such as via utilization of next-generation sequencing assays that detect specific genomic alterations, and novel therapy combinations that include HER2– targeting agents (with immunotherapy or other modalities) may lead to improved outcomes in current, ongoing or future trials. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bladder Cancer IOS Press

Systematic Review: Targeting HER2 in Bladder Cancer

Download PDF
12 pages

Loading next page...
 
/lp/ios-press/systematic-review-targeting-her2-in-bladder-cancer-fc9O7Vc7Lo

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2019 © 2019 – IOS Press and the authors. All rights reserved
ISSN
2352-3727
eISSN
2352-3735
DOI
10.3233/BLC-180196
Publisher site
See Article on Publisher Site

Abstract

Background:HER2 (ErbB2) is a receptor of the Human Epidermal Growth Factor Receptor (HER) family whose role in oncogenesis of numerous malignancies is well described. Drugs targeting HER2 are currently approved in breast and gastroesophageal cancers while pan-HER targeting agents are being evaluated in multiple malignancies. HER2 genomic alterations are commonly described in urothelial cancer and multiple trials have assessed the efficacy of anti-HER2 agents in both muscle-invasive and metastatic urothelial carcinoma.Objective:To review prospective clinical trials of therapeutic agents with HER2– targeting activity in patients with bladder cancer.Methods:A systematic search of PubMed, ASCO abstracts and Clinicaltrials.gov was performed to identify studies of HER2– targeting agents in bladder cancer. Reported results from prospective trials were reviewed and summarized.Results:Eleven prospective clinical trials with reported results were identified that investigated activity of trastuzumab, lapatinib, neratinib, afatinib, or autologous cellular immunotherapy (DN24–02) in various bladder cancer treatment settings. Another 11 prospective trials that include bladder cancer patients and are investigating agents with anti-HER2 activity are currently ongoing or have completed enrollment but do not have published results. The reported clinical trials had variable HER2– positivity inclusion criteria and most did not meet their pre-specified benchmarks of clinical efficacy. A recent afatinib trial in an unselected patient population had promising findings in patients with HER2 and HER3 alterations.Conclusion:Trials of HER2– targeting agents generally in unselected bladder cancer patients have not shown definitive clinical efficacy. Better patient selection, such as via utilization of next-generation sequencing assays that detect specific genomic alterations, and novel therapy combinations that include HER2– targeting agents (with immunotherapy or other modalities) may lead to improved outcomes in current, ongoing or future trials.

Journal

Bladder Cancer – IOS Press

Published: Jan 1, 2019

References

  • Cancer statistics, 2018
    Siegel
  • Neoadjuvant chemotherapy in invasive bladder cancer. Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration
  • Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    von der Maase
  • M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium
    Sternberg
  • A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
    Loehrer
  • Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924
    Sternberg
  • Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
    von der Maase
  • A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
    Galsky
  • Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986
    De Santis
  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial
    Balar